Key facts
- This page summarizes OPKO HEALTH, INC.'s Form 4 filing for GeneDx Holdings Corp. (WGS).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2024, 17:23.
OPKO HEALTH, INC. - 15 Aug 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- WGS
- Reported as of
- 15 Aug 2024
- Net transaction value
- -$4,756,875
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2024, 17:23:52 UTC
- Prior SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- Steven D. Rubin, Exec. VP - Administration
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
OPKO HEALTH, INC. filed Form 4 for GeneDx Holdings Corp. (WGS) on 19 Aug 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: -$4,756,875.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WGS
transaction
Class A Common Stock
Sale
- Transaction value
- $1,317,505
- Shares
- -39,824
- Change %
- -1.4%
- Price
- $33.08
- Shares after
- 2,746,972
- Date
- 15 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
WGS
transaction
Class A Common Stock
Sale
- Transaction value
- $1,714,850
- Shares
- -50,000
- Change %
- -1.8%
- Price
- $34.30
- Shares after
- 2,696,972
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
WGS
transaction
Class A Common Stock
Sale
- Transaction value
- $1,724,520
- Shares
- -50,000
- Change %
- -1.9%
- Price
- $34.49
- Shares after
- 2,646,972
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
OPKO HEALTH, INC. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.
Footnote F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4.